MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population

Carcinogenesis

Volumn 29, Issue 4, 2008, Pages 754-761

  Lum, San San ^a   Chua, Hui Wan ^a   Li, Huihua ^a   Li, Wen Feng ^b,d   Rao, Nanyan ^b   Wei, Jin ^b   Shao, Zhiming ^b   Sabapathy, Kanaga ^a,c  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b FUDAN UNIVERSITY   (China)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN MDM2; PROTEIN P53;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CAUCASIAN; CHINESE; CODON; CONTROLLED STUDY; ETHNIC DIFFERENCE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; CODON; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GUANINE; HUMANS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN; RISK FACTORS;

EID: 41849110219     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn024     Document Type: Article

References (45)

1. Ferlay,J. et al. (2001) GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. Version 10. IARC, Lyon.
2. Batori,M. et al. (2006) Breast cancer in young women: Case report and a review. Eur. Rev. Med. Pharmacol. Sci., 10, 51-52.
3. Giuliano,A.E. (1998) Breast. In Tierney,L.M., McPhee,S.J., and Papadakis M.A. (eds.) Current Medical Diagnosis and Treatment. Stamford, CT, Appleton and Lange, pp. 666-690.
4. Collaborative Group on Hormonal Factors in Breast Cancer. (2001) (2001) Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 358, 1389-1399.
5. Seow,A. et al. (2004) Trends in Cancer Incidence in Singapore 1968-2002. Singapore Cancer Registry Report 6. Singapore: Singapore Cancer Registry.
6. Yu,K. et al. (2004) Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin. Cancer Res., 10, 5508-5517.
7. Bray,F. et al. (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res., 6 229-239.
8. Vousden,K.H. et al. (2002) Live or let die: The cell's response to p53. Nat. Rev. Cancer, 2, 594-604.
9. Olivier,M. et al. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat., 19 607-614.
10. Petitjean,A. et al. (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 26, 2157-2165.
11. Frebourg,T. et al. (1992) Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Proc. Natl Acad. Sci. USA, 89, 6413-6417.
12. Varley,J.M. et al. (1997) Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res. 57, 3245-3252.
13. Dumont,P. et al. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33 357-365.
14. Siddique,M. et al. (2006) Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene, 25, 3489-3500.
15. Pim,D. et al. (2004) P53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer, 108, 196-199.
16. Storey,A. et al. (1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature, 393, 229-234.
17. Sjalander,A. et al. (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-1316.
18. Weston,A. et al. (1997) Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: A meta-analysis. Environ. Health Perspect. 105, 919-926.
19. Papadakis,E.N. et al. (2000) P53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol. Cell Biol. Res. Commun., 3, 389-392.
20. Damin,A.P. et al. (2006) Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect. Prev., 30, 523-529.
21. Khadang,B. et al. (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet. Cytogenet., 173, 38-42.
22. Mabrouk,I. et al. (2003) No evidence of correlation between p53 codon 72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients. Ann. N. Y. Acad. Sci., 1010, 764-770.
23. Buyru,N. et al. (2003) P53 codon 72 polymorphism in breast cancer. Oncol. Rep., 10, 711-714.
24. Matakidou,A. et al. (2003) TP53 polymorphisms and lung cancer risk: A systematic review and meta-analysis. Mutagenesis, 18 377-385.
25. Koushik,A. et al. (2004) P53 codon 72 polymorphism and cervical neoplasia: A meta-analysis review. Cancer Epidemiol. Biomarkers Prev. 13, 11-22.
26. Beckman,G. et al. (1994) Is p53 polymorphism maintained by natural selection? Hum. Hered., 44, 266-270.
27. Siddique,M.M. et al. (2005) Evidence for selective expression of the p53 codon 72 polymorphs: Implications in cancer development. Cancer Epidemiol. Biomarkers Prev., 14, 2245-2252.
28. Bond,G.L. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
29. Harris,S.L. et al. (2005) Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc. Natl Acad. Sci. USA, 102, 16297-16302.
30. Bond,G.L. et al. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res., 66 5104-5110.
31. Bond,G.L. et al. (2007) A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene, 26, 1317-1323.
32. Balram,C. et al. (2002) Genetic polymorphisms of UDP-glucuronosyltransferase in Asians: UGT1A1*28 is a common allele in Indians. Pharmacogenetics, 12, 81-83.
33. Thakkinstian,A. et al. (2005) A method for meta-analysis of molecular association studies. Stat. Med., 24, 1291-1306.
34. Campbell,I.G. et al. (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett., 240, 195-197.
35. Boersma,B.J. et al. (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J. Natl Cancer Inst., 98 911-919.
36. Copson,E.R. et al. (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer, 6, 80.
37. Lynch,H.T. et al. (2004) Cancer in Jews: Introduction and overview. Fam. Cancer, 3, 177-192.
38. Ma,H. et al. (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population. Cancer Lett., 240, 261-267.
39. Toyama,T. et al. (2007) Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res., 9, R34.
40. Kinyamu,H.K. et al. (2003) Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression. Mol. Cell. Biol., 23, 5867-5881.
41. Qi,J.S. et al. (1999) Regulation of the mdm2 oncogene by thyroid hormone receptor. Mol. Cell. Biol., 19, 864-872.
42. Wasielewski,M. et al. (2007) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res. Treat., 104, 153-157.
43. Petenkaya,A. et al. (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res., 26, 4975-4977.
44. Zhou,G. et al. (2007) MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin. Cancer Res., 13, 2627-2633.
45. Ohmiya,N. et al. (2006) MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J. Clin. Oncol., 24, 4434-4440.